SUN-210 - Efficacy and Safety of Combined Growth Hormone and Letrozole Therapy in Adolescents with Idiopathic Short Stature

Indroduction: Adolescents with idiopathic short stature (ISS) pose a therapeutic challenge
due to the decreased efficacy of growth hormone (GH) treatment, attributed to accelerated skeletal maturation induced by sex steroids and premature fusion of growth plate leading to final short stature.

Methods: Adolescent males were included with bone age between 12-14 years without
genetic or hormonal alteration, Letrozol 2.5 mg and Growth Hormone 0.04 mg / kg / day were started. Patients were evaluated every 3 months till final height defined as bone age 15 years or growth velocity below 1 cm during 6 months. Adult final height was calculated using the Bayley-Pinneau method. Data is expressed as mean ± standard deviation (M ± SD).

Results: 31 male adolescents were included. Initial age was 11.8 years ± 1.3; Initial height
was 146.2 cm ± 7.6 with an initial bone age of 12.6 ± 1.1 . Projected Adult height was
162.8 cm ± 3.4 and final height was 168.2 cm ± 3.1 , with a total increase of 5.4 cm in final
height . Duration of therapy was 2.8 ± 0.4 years No side effects were observed during the
therapy.

Conclusion: In adolescent males with ISS and bone age over 12 years, combined therapy
with growth hormone and Letrozol significantly improves adult height with no side effects
observed during the therapy.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*